Virtu Financial’s Cytek Biosciences CTKB Stock Holding History

Virtu Financial’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,026	Closed	-$118K	–	1720
2026 Q1	$118K	Buy	+27,026	New	+$128K	﹤0.01%	1161

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtu Financial's CTKB Position: Q2 2026 in Review

Virtu Financial sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 27,026 shares — an estimated $118K sold.

Virtu Financial first reported a position in CTKB in Q1 2026 and held it in 1 quarter. The position peaked at $118K in Q1 2026. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Virtu Financial reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 27,026 Cytek Biosciences shares in Q2 2026, an estimated $118K.
Virtu Financial first reported a position in Cytek Biosciences in Q1 2026 and held it in 1 quarter.
Virtu Financial's Cytek Biosciences position peaked at $118K in Q1 2026.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.